中国生物制药(01177.HK) 公布,已在2025年美国临床肿瘤学会(ASCO)年会公布贝莫苏拜单抗注射液联合化疗后序贯联合盐酸安罗替尼胶囊,对比替雷利珠单抗注射液联合化疗,用于晚期鳞状非小细胞肺癌(sq-NSCLC)一线治疗的III期临床最新研究成果。
试验组中位无进展生存期(mPFS)为10.12个月,与对照组相比疾病进展风险降低36%。(jl/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-23 16:25。)
中国生物制药(01177.HK) 公布,已在2025年美国临床肿瘤学会(ASCO)年会公布贝莫苏拜单抗注射液联合化疗后序贯联合盐酸安罗替尼胶囊,对比替雷利珠单抗注射液联合化疗,用于晚期鳞状非小细胞肺癌(sq-NSCLC)一线治疗的III期临床最新研究成果。
试验组中位无进展生存期(mPFS)为10.12个月,与对照组相比疾病进展风险降低36%。(jl/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-23 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.